SCHEDULE: Insider Sells VOR Biopharma Shares, Ownership Drops to 26.8%

Reprogrammed Interchange LLC and Reid Hoffman have reduced their stake in VOR Biopharma Inc. through recent open market sales, now holding 26.8% of common stock.

Summary

• Reprogrammed Interchange LLC and Reid Hoffman, as Reporting Persons, filed Amendment No. 3 to their Schedule 13D for VOR Biopharma Inc.
• Between September 8, 2025, and September 11, 2025, Reprogrammed Interchange LLC sold a total of 1,548,452 shares of VOR Biopharma common stock in open market transactions.
• These sales occurred at weighted average prices ranging from $1.8151 to $2.0004 per share.
• The sales resulted in a decrease in the Reporting Persons' beneficial ownership by more than one percent of the outstanding shares.
• Additional sales by Reprogrammed Interchange LLC during the past 60 days (August 25, 2025, to September 5, 2025) totaled 3,497,162 shares, with weighted average prices ranging from $1.9285 to $2.1163.
• Following these transactions, the Reporting Persons beneficially own 33,928,487 shares, representing 26.8% of VOR Biopharma Inc.'s common stock.
• The Reporting Persons retain shared voting and dispositive power over all beneficially owned shares.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a major shareholder, which typically signals reduced confidence or a strategic exit, potentially putting downward pressure on the stock price.

Negatives

• Significant insider selling by Reprogrammed Interchange LLC and Reid Hoffman, indicating a reduction in their stake.
• The sales decreased beneficial ownership by more than one percent of outstanding shares, potentially signaling a lack of confidence or a strategic shift by a major investor.
• The sales occurred at prices ranging from $1.8151 to $2.1163, which could put downward pressure on the stock price.

Risks

• The reduction in a significant investor's stake could be perceived negatively by the market, potentially leading to decreased investor confidence.
• Continued selling by large shareholders could exert downward pressure on the company's stock price.

Future Outlook

NA

Industry Context

This filing reflects a significant investor's decision to reduce their stake in a biopharmaceutical company. While the specific reasons for the sales are not disclosed, such actions by major shareholders can sometimes precede or coincide with broader industry trends, such as shifts in investment focus or re-evaluation of sector-specific risks. Without further context on VOR Biopharma's operational performance or the broader biotech market, it's difficult to draw definitive conclusions about industry-wide implications.

Stakeholder Impact

• Shareholders: Existing shareholders may experience downward pressure on the stock price due to the increased supply of shares from the selling party and potential loss of confidence following a major investor's divestment.
• Potential Investors: May view the significant insider selling as a negative signal, potentially deterring new investment or leading to a more cautious valuation.

Key Dates

Recommendation

The consistent and significant selling by a major beneficial owner, Reprogrammed Interchange LLC and Reid Hoffman, suggests a lack of confidence or a strategic exit from their position in VOR Biopharma. Such large-scale insider selling, especially when it reduces ownership by more than one percent of outstanding shares, typically signals a negative outlook from those with deep insight into the company. This action is likely to exert downward pressure on the stock price and could erode broader market confidence, making a 'sell' recommendation prudent for investors seeking to mitigate potential losses or reallocate capital.

Keywords

VOR Biopharma, VOR, Reprogrammed Interchange LLC, Reid Hoffman, Schedule 13D/A, insider selling, share sale, beneficial ownership, common stock, biotech, biopharma